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Prudent use of antibiotics
S U M M A R Y
Background: Acute and chronic respiratory tract infections are a common cause of inappropriate
antimicrobial prescription. Antimicrobial therapy leads to the development of resistance and the
emergence of opportunistic pathogens that substitute the indigenous microbiota.
Methods: This review explores the major challenges and lines of research to adequately establish the
clinical role of bacteria and the indications for antimicrobial treatment, and reviews novel therapeutic
approaches.
Results: In patients with chronic pulmonary diseases and structural disturbances of the bronchial tree or
the lung parenchyma, clinical and radiographic signs and symptoms are almost constantly present,
including a basal inﬂammatory response. Bacterial adaptative changes and differential phenotypes are
described, depending on the clinical role and niche occupied. The respiratory tract has areas that are
potentially inaccessible to antimicrobials. Novel therapeutic approaches include new ways of
administering antimicrobials that may allow intracellular delivery or delivery across bioﬁlms, targeting
the functions essential for infection, such as regulatory systems, or the virulence factors required to
cause host damage and disease. Alternatives to antibiotics and antimicrobial adjuvants are under
development.
Conclusions: Prudent treatment, novel targets, and improved drug delivery systems will contribute to
reduce the emergence of antimicrobial resistance in lower respiratory tract infections.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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As a medical microbiologist, reporting the results of suscepti-
bility testing of a non-primary pathogenic microorganism isolated
from the respiratory tract may be discouraging, both when it is
susceptible and when it is multidrug-resistant (MDR). The clinical
consequence of such a report is often the prescription of
antimicrobial treatment, even without clinical symptoms. Thera-
peutic decisions are a daily clinical challenge. What is the clinical
role of a MDR Pseudomonas aeruginosa or a methicillin-resistant
Staphylococcus aureus (MRSA) isolated from the sputum of a
chronic pulmonary obstructive disease (COPD) patient with a
moderate exacerbation, or when isolated from the endotracheal
aspirate of a ventilated patient who simultaneously presents
Escherichia coli bacteremia?* Corresponding author. Tel.: +34 93 497 88 94.
E-mail address: crisprat2010@gmail.com (C. Prat).
http://dx.doi.org/10.1016/j.ijid.2016.09.005
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Huge progress has been made in imaging and bronchoscopic
techniques and these have improved the diagnosis of neoplasia,
lower respiratory tract infections (LRTI), and tuberculosis. In
addition, the development of highly sensitive molecular biology
assays and mass spectrometry have increased the detection of
respiratory pathogens. However, the clinical role of bacteria whose
normal ecological niche is the airways, where healthy carriage
dominates over disease, is still an unresolved issue,1 and very
sensitive techniques need to be interpreted with caution. Many
efforts have also been directed at identifying novel therapeutic
approaches, but it is ﬁrst crucial to clearly establish when it is
really necessary to treat and what the adequate duration of
treatment is. The unnecessary use of extended-spectrum anti-
biotics in patients infected with non-resistant organisms and the
inappropriate use of ﬁrst-line antibiotics in patients infected with
resistant organisms contribute to the emergence and spread of
resistance.2,3 Acute and chronic respiratory tract infections are the
most frequent causes of antimicrobial prescription in primary care,
the hospital setting, and health care facilities.4 The respiratory tractciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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microorganisms such as S. aureus and P. aeruginosa.
Antibiotic resistance is the evolutionary response to the strong
selective pressure that results from exposure to the use of these
drugs in the clinic and in livestock feed, and it needs to be
curtailed.5 There is a correlation between antimicrobial usage and
resistance, increasing from north to south in Europe,6 although
some situations such as the emergence of community-acquired
(CA) MRSA epidemics are not so easy to explain.7 The availability of
antibiotics has enabled revolutionary medical interventions such
as cancer chemotherapy, organ transplantation, and all major
invasive surgeries,5 but patients are exposed to infections by MDR
bacteria, which impacts on morbidity and mortality. The presence
of a MDR microorganism is troublesome even when only
colonizing, because of its social and economic impact due to the
required contact isolation measures.
Antimicrobial usage in LRTI also leads to the emergence of
opportunistic pathogens that substitute the indigenous micro-
biota, such as constitutively resistant non-glucose-fermenting
Gram-negative bacilli, Aspergillus, Actinomycetales, and environ-
mental mycobacteria.5 Finally, even when an apparently appro-
priate therapy is prescribed, the respiratory tract has areas that are
potentially inaccessible to antimicrobial entry due to collapse or
oedema, but also because of microbial adaptation mechanisms
such as bioﬁlm formation and intracellular persistence. Consider-
ing all the aforementioned reasons, respiratory tract infections are
often mismanaged regarding the correct diagnosis, indication,
dosage, and duration of antimicrobial treatment. In addition, the
immunity of several opportunistic pathogens adapted to the
respiratory tract is not completely understood, so vaccine
development remains challenging.8,9
2. Microbiological detection: bronchial colonization or
respiratory tract infection?
The respiratory tract is not a sterile site,10 and the composition
of the indigenous microbiota evolves in relation to factors such as
the hormonal environment, ecological disturbances, and antimi-
crobial use.11 The resident microbiome includes microorganisms
that are also potential aetiological agents of respiratory tract
infections, such as Streptococcus pneumoniae, non-typeable Hae-
mophilus inﬂuenzae, and S. aureus. Airway inﬂammation, altered
mucus production, and diminished mucociliary clearance contrib-
ute to colonization in several situations. S. aureus carriage in the
upper airways may be occasional or persistent,12 and its success as
a component of the respiratory ﬂora is determined by its ability to
scavenge iron and coordinate gene expression, as well as the
horizontal acquisition of useful genetic elements.13 S. pneumoniae1
and H. inﬂuenzae14 are present in the nasopharynx (a highly
oxygen-exposed region) of up to 60% of preschool children, as well
as in patients with underlying pulmonary diseases. The establish-
ment of colonization is a prerequisite for the development of
pneumococcal disease through a combination of virulence factor
activity and the ability to evade the early components of the host
immune response to compete with other microorganisms.15
Colonization by P. aeruginosa requires an underlying pathology,16
but it is also possible without active infection.
Quantitative measurements of bacterial load have failed to clear
up the situation: respiratory samples are heterogeneous and often
not comparable one to another, although bacteriological response is
a parameter used in clinical trials to assess efﬁcacy. The validity of
microbiological tests is improved by strict case deﬁnition and
adequate radiographic review, but in the absence of positive blood
cultures, a gold standard is lacking and the variability of sputum
quality and contamination with oropharyngeal bacteria is still
determinant, even when molecular detection is positive.17 Even apositive urinary antigen detection may be the result of coloniza-
tion.18,19 Comprehensive molecular testing including bacterial load
quantitation signiﬁcantly improves pathogen detection and may
improve early antimicrobial de-escalation,20 but PCR is able to
detect dead as well as viable bacteria and a clinical improvement is
sometimes observed without a decrease in the bacterial inoculum.
The recently published hospital-acquired pneumonia (HAP) and
ventilator-associated pneumonia (VAP) guidelines recommend
non-invasive sampling with semiquantitative cultures, since the
evidence suggests that clinical outcomes are similar regardless of
whether specimens are obtained invasively or non-invasively, and
whether cultures are performed quantitatively or semiquantita-
tively, although a lower risk of inadequate initial antibiotic coverage
may be observed and facilitates antibiotic de-escalation.21
Microorganisms may persist in the respiratory tract for a long
time even when prescribed antimicrobials have been expected to
be active based on conventional in vitro susceptibility testing.22 As
reviewed below, members of the indigenous microbiota and even
newly acquired microorganisms have evolved to adapt,16 at least
temporarily, to the anatomical site and nutrient environment
where they secure a niche. A hypothesis is that lymphatic tissue
associated with the respiratory tract allows the immune system to
contain pathogens and conﬁne them to their carrier niche, and
occasional failure and disturbances in homeostasis result in
disease.1
Infection is the establishment of a microorganism within a host,
while infectious disease applies when the interaction causes
damage or an altered physiology resulting in clinical signs and
symptoms.23 The distinction is particularly difﬁcult in patients
with chronic pulmonary diseases and structural disturbances of
the bronchial tree (bronchiectasis) or the lung parenchyma
(pulmonary neoplasia, lobectomy/pneumonectomy, or tuberculo-
sis scars) in whom clinical and radiographic signs and symptoms
are almost constantly present, including a persistent systemic
inﬂammation.24
Several new assays and technologies have come into clinical
use, such as matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF MS) and gene expression
proﬁling.25 This last approach using microarrays has potential
value as a diagnostic test, once validated through multi-cohort
analyses to identify diagnostic gene sets,26 since it uses the host
response to pathogens as a means of diagnosing infection, rather
than direct pathogen detection, or response through a speciﬁc
biomarker, generating a snapshot of the immune response.25
3. Bacterial adaptation to the respiratory tract
For opportunistic pathogens that can either reside asymptom-
atically or cause symptomatic infections, the deﬁnition of success
becomes increasingly complex.27 Bacteria develop adaptative
mechanisms to the respiratory tract in order to survive in hostile
environments related to factors such as co-infecting species and
antimicrobial therapies, as well as lung conditions such as
inﬂammatory response, hypoxia, or nutrient deﬁciency16
(Figure 1). Adaptation mechanisms include exopolysaccharide
production (mucoid phenotypes), loss in motility, formation of
small colony variants (SCV), and an increased mutation rate, as
well as changes in quorum sensing (QS) and in the consequent
production of virulence factors.
In many cases, especially those associated with indwelling
medical devices such as an orotracheal tube, the formation of
bioﬁlm may explain the persistent isolation of S. aureus, H.
inﬂuenzae, or P. aeruginosa. In fact, the natural state of many
bacteria is one where they are associated with surfaces, in which
acting as a ‘community’ increases their possibility of survival.
Bioﬁlm-associated bacteria tend to be less susceptible to treatments
Figure 1. Key host, microorganism, and drug factors during colonization and infection in respiratory tract infections.
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bacteria. It is considered that mixed species bioﬁlms are the
dominant form and that the cell–cell communication (i.e., QS) may
condition changes in the composition of extracellular polymeric
substances, bioﬁlm resistance to antimicrobial agents, and envi-
ronmental stress conditions.28,29
In addition, there is accumulating evidence that aside from the
classically deﬁned intracellular pathogens, microorganisms like
S. aureus and P. aeruginosa are also able to survive within eukaryotic
host cells and might be termed opportunistic intracellular patho-
gens, constituting a reservoir for recurrence and infection,30 residing
in the nasal mucosa or lung parenchyma.31,32 This immune-evasive
strategy shields microorganisms from many of the humoral and
cellular defence mechanisms and also protects them from
antimicrobial treatment. Treatment with antibiotics that act poorly
intracellularly may foster the selection of resistant mutants,33 and
interactions between species will inﬂuence the antibiotic resistance
and pathogenicity of a mixed bacterial community.28
Several studies have suggested that circulating macrophages or
neutrophils could act as a ‘Trojan horse’ for pathogenic bacteria,
allowing their dissemination in systemic infections.34 Cell models
employing non-professional phagocytes (i.e. airway epithelial and
endothelial cells) and professional phagocytes (neutrophils and
macrophages) have documented different strategies, such as
escape from the phagosome into the cytoplasm or survival in
phagolysosomes.35–39 Virulence factors or global regulatory
systems have been found to contribute to intracellular survival
mechanisms, as elegantly reviewed elsewhere.40–42
Antibiotic use may also modulate the expression of genes
involved in the transition to an intracellular lifestyle.43,44 Bacteria
may exhibit subpopulations with a slow growth rate, such as the
semi-dormant state with a metabolically quiescent phenotype of
SCV,45,46 mostly described in S. aureus but also in P. aeruginosa.47
Antimicrobial compounds may also enhance the formation of SCV,
promoting chronic infections.45 Mucoid phenotypes are common
adaptation mechanisms for S. pneumoniae and P. aeruginosa.484. Treatment decisions
4.1. Clinical and radiological features
Acute LRTI is deﬁned as an acute illness (present for 21 days or
less), usually with cough as the main symptom, and with at least
one other lower respiratory tract symptom (fever, sputum
production, breathlessness, wheeze, or chest discomfort or pain)
and no alternative explanation (such as sinusitis or asthma).
Pneumonia, acute bronchitis, and exacerbations of chronic
obstructive airway disease are included in this deﬁnition.2
Chest radiography has become an imperfect gold standard
for the diagnosis of pneumonia, since it may be distorted by
co-existing co-morbidities and there is inter-observer variability.17
In a recent study, early multidetector computed tomography chest
scans led to changes in the initial diagnosis and in patient
management, both excluding and revealing pulmonary involve-
ment.49 Alternative diagnoses are, as previously reported, acute
exacerbations of COPD (AECOPD) and acute heart failure.50
Regarding AECOPD, viruses are often considered the responsible
agent,51 and the presence of bacteria may be the result of
colonization.52 However, antimicrobials were prescribed in 85% of
AECOPD in a cohort study in the USA.53 Systematic reviews do not
conclude on the real beneﬁt of antibiotic use in exacerbations, and
a randomized double-bind placebo controlled study is ongoing to
demonstrate that antibiotics are not needed in moderate acute
exacerbations of COPD.54
Regarding patients undergoing mechanical ventilation through
an orotracheal tube or carrying a tracheostomy, surveillance
endotracheal aspirate cultures are used to guide antimicrobial
therapy.55 In patients with ventilator-associated tracheobronchitis
(VAT), antibiotic treatment has been reported to be associated with
signiﬁcantly lower intensive care unit (ICU) mortality and subse-
quent VAP rates, as well as more mechanical ventilator-free days,
but this could be explained by the reduction in secretion volume
and tracheobronchial inﬂammation,56 without a signiﬁcant impact
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Therefore, current guidelines even suggest not providing antibiotic
therapy in VAT.21 Substantial efforts have been made to develop
short-course therapies and antibiotic de-escalation.
4.2. Inﬂammatory biomarkers and severity scores
The inﬂammatory response and acute lung injury evoked by the
microorganisms are determinant in the pathogenesis and outcome
of LRTI. The use of systemic biomarkers has been evaluated
extensively in different settings.57,58 Single and serial measure-
ments can be seen as a complementary tool for diagnosis,
assessment of the prognosis, and antibiotic therapy decisions
(use and duration),25 but it is still suboptimal for adequate
stratiﬁcation.59,60 In addition, there are some factors that can
inﬂuence biomarker secretion, such as the presence of speciﬁc co-
morbidities (mostly cardiac and renal) or the use of previous
antibiotic and steroid treatment. The National Institute for Health
and Care Excellence guidelines recommend using the results of
C-reactive protein (CRP) testing to guide antibiotic prescription in
people without a clinical diagnosis of pneumonia. However, the
inﬂammatory response may be different depending on whether
the aetiology is bacterial or viral,61–63 and even some virulence
factors, including immune evasion molecules, may silence the
systemic inﬂammatory response.37 HAP and VAP guidelines do not
include CRP, procalcitonin, or soluble triggering receptor expressed
on myeloid cells 1 (sTREM-1) in algorithms for treatment
decisions, although levels are used when guiding antibiotic
discontinuation.21
Severity assessed by oxygen level is not necessarily related to
infection in patients with pneumopathy. Severity scores are based
on clinical, radiological, and biochemical abnormalities, and relate
to the risk of death, but they are not necessarily related to the
infection process itself. An approach combining biomarker levels
with scores64–66 does improve sensitivity and speciﬁcity for the
identiﬁcation of high-risk patients, and thus provides a more
accurate stratiﬁcation.
4.3. Detection of virulence factors
Whether the infecting microorganism has to be eliminated or
just become unharmful by reducing disease severity is a clinical
challenge. Successful infection depends on a vast array of microbial
virulence factors that are not essential for viability but are required
for pathogenesis. Each physiological niche comprises speciﬁc
environmental characteristics, which differentially affect bacterial
gene expression, orchestrated by regulatory systems based on the
QS. Some virulence factors have been considered determinant in
the pathogenesis of infection, and assays including point-of-care
tests have been developed to detect them.67–71 However, the role
of Panton–Valentine leukocidin from S. aureus in necrotizing
pneumonia caused by USA300 strains has been the subject of
controversy, since other factors from the core genome, such as
phenol soluble modulins (PSM) or alpha-haemolysin, may
contribute to virulence.13,40 Alpha toxin is responsible for cytotoxic
effects in multiple cell types and has a determinant role in tissue
damage and lung injury.72 Other staphylococcal factors involved in
respiratory tract infections are the toxic shock syndrome toxin,
protein A, beta toxin, and enterotoxin.13 Co-expression of several
factors simultaneously or sequentially is most likely.
Virulence factors from S. pneumoniae that have been used for
the development of diagnostic methods or as vaccine antigens
include pneumolysin, essential for the survival of the microorgan-
ism in both the upper and lower respiratory tract,1,15 and also cell-
surface proteins and capsular and C-polysaccharides, detected by
urinary antigen detection tests.73 The pathogenesis of infection bynon-typeable H. inﬂuenzae strains is predominantly by contiguous
spread,14 so it depends on changes in immune status and bioﬁlm
formation. Recently the role of P5 and Hap surface proteins in
virulence has been described.74 QS components may modulate the
virulence of P. aeruginosa by regulating the synthesis of phenazines
such as pyocyanin,75,76 but also lectins, exotoxins, or elastase.
Lipopolysaccharide is the most important immune-stimulator in
Gram-negative bacteria and tests to detect endotoxin have been
developed.77 The presence of speciﬁc antibodies in human clinical
samples, such as alpha toxin antibodies from S. aureus78 and
exopolysaccharide PcrV and polysaccharide synthesis locus (Psl)
from P. aeruginosa,79,80 has been associated with an improved
outcome. All of these virulence factors could be regarded as
potential targets for treatment, but the diagnostic role of serum
antibody detection is still not clear.
5. Studies needed to understand the host–pathogen
interaction
Daily clinical observation is the ﬁrst step when assessing a
patient’s response to infection. Large observational studies are
required to clearly deﬁne the epidemiology and natural history of
respiratory infections and to assess whether microbial factors in
combination with clinical and epidemiological features correlate
with asymptomatic carriage or increase the risk of an adverse
outcome. In this sense, the New Drugs for Bad Bugs (ND4BB)
programme, an Innovative Medicines Initiative, has the ultimate
goal of boosting the ﬁght against antimicrobial resistance through
basic science and drug discovery, as well as clinical development
and the responsible use of antibiotics.81 The genetic variations
among individual isolates and variations in susceptibility among
different individuals creates a spectrum of interactive events that
may shift the balance towards commensalism or towards disease.1
Several studies are exploring the association between single
nucleotide polymorphism (SNPs) and predisposition to disease.82
Adequate in vitro cell models and animal models close to the
clinical situation are critical, including real-time imaging within
speciﬁc organs, such as the lungs, and mathematical modelling.23
Novel high-throughput sequencing technologies (next-genera-
tion sequencing, NGS), although producing copious ‘big data’, open
up new possibilities for analysis of genome-wide associations and
functional genomic approaches and provide insights into bacterial
evolution and disease aetiology.83–86 Distinct bacterial genotypes
may be linked to speciﬁc disease phenotypes,87,88 and in the case of
non-primary pathogens, may allow the demonstration that
toxicity does not always correlate with severity.27 Our capacity
to acquire ‘omics’ data about infections is increasing exponentially,
and substantial efforts in bioinformatic and systems biology
approaches are needed to connect data into a pipeline and make it
manageable. The objective would be to integrate NGS with
electronic medical records, immune proﬁling data, and other
datasets to create multiscale predictive models that may help not
only to combine properties associated with disease, but also to
improve antimicrobial stewardship.88,89. Metabolomics and secre-
tomics in accessible clinical samples may assess host–pathogen
interactions, because metabolites are seen as terminal down-
stream end products, whose presence and concentration reﬂect
changes occurring at the gene, transcription, and translation
level.16,90–92 Transcriptomic analysis of samples from in vivo
infection or colonization is very limited,93 and should help in
understanding the switch from carriage to infection.
6. Novel therapeutic approaches
Over-prescription of antibiotics in respiratory tract infections
must be reduced by identifying the correct indications, as
Figure 2. Future approaches for the treatment of respiratory tract infections: description of alternatives.
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and the duration of treatment. Also, pharmacokinetic/pharmaco-
dynamic (PK/PD) optimized dosing and de-escalation are strate-
gies to combat resistance.21 Improved detection of the causative
agent is essential for appropriate antimicrobial stewardship.94 In
terms of novel developments, the pharmaceutics pipeline is
becoming less productive. However, there is better knowledge
of natural product biosynthesis and new approaches for the
development of synthetic compounds with improved antibiotic
properties,95 so some new antimicrobials for the treatment of
respiratory tract infections have been licensed in recent years and
are available.96 A recent review focusing on systemic infections
addresses alternatives to antibiotics including approaches
that target the bacteria or the host.97 Furthermore, there is a
need for more imaginative ways of administering treatment.
Figure 2 summarizes key factors for the improvement of
antimicrobial options in LRTI.
6.1. Lung penetration
As a general principle, the antimicrobial of choice has to be
appropriate (pathogen is susceptible) and adequate (high enough
level of the drug at the site of infection). For the ﬁrst aspect,
pathogen-directed therapy guided by in vitro microbiological data
is a safe approach;3 as an example, penicillins are still the ﬁrst
option for S. pneumoniae in many settings. For the second aspect, as
is obvious, a prerequisite for antimicrobial activity is that the
bacteria and antibiotics come into contact in the same compart-
ment. Due to the unique structure of the lung, it is not always
possible to deliver microbiologically active concentrations of
antimicrobials to the appropriate parts.98 Furthermore, it is also
important that the antimicrobials are not inactivated by pulmo-
nary surfactant,99 pH, or enzymes. Activity studies are based on
serum concentrations, but distribution into the pulmonary tissue
may be insufﬁcient. This may also be the case in anatomical
cavities and areas of collapse or oedema, as well as in bacterialinfections with evidence of bioﬁlm formation and co-localization
in intracellular compartments, where it will depend on cellular
drug accumulation and subcellular distribution.30 Lung penetra-
tion has been highly debated in the treatment of MRSA
pneumonia.100 An adequate duration of therapy is crucial not
only to prevent the development of resistance, but also the
development of persistent phenotypes, which have a different
in vitro susceptibility proﬁle.
6.2. Intracellular targeting
Because of potential simultaneous intracellular and extracellu-
lar bacterial foci and different metabolic states, targeting the
mechanisms of bacterial adaptation to the intracellular environ-
ment represents a novel therapeutic strategy. Combined therapies
may have a role, in a similar way as in tuberculosis and as
hypothesized for systemic34 and osteoarticular infections.101
There are substantial differences in PK/PD properties of the
different classes of antibiotics. In general, beta-lactams, aminogly-
cosides, and vancomycin have restricted cellular penetration owing
to their high hydrophobicity. On the other hand, although
ﬂuoroquinolones and macrolides diffuse well into cells, they
display low intracellular retention.33 Oritavancin accumulation in
lysosomes is high and does not affect macrophage function.102 Local
acidity is also important, i.e., aminoglycosides accumulate in the
lysosomal cell compartment but are extremely pH susceptible,103
and, interestingly, MRSA can become methicillin-susceptible when
intracellular because penicillin binding protein 2a (PBP2a) is
modiﬁed by an acidic pH.104,105 Cell-penetrating peptides have
also been screened, but still have decreased efﬁcacy.106
6.3. Nanocarriers and lipid formulations
Nowadays it is possible to encapsulate, incorporate, or even
conjugate biologically active molecules into different families of
nanocarriers such as liposomes or nanoparticles. The encapsulation
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of the commensal microbiota. Optimal nanocarriers need to be
biocompatible and biodegradable and able to deliver the drug to the
correct place and at a therapeutic concentration, and must not burst
and release the encapsulated drug before reaching the target site.
Drug delivery platforms include among others liposomes, micelles,
and nanotubes and polymeric nanoparticles.107
Among nanodevices, liposomal formulations are the best
known and most widely investigated. It is feasible to manipulate
the composition: indeed it is possible to change the size, surface
charge, sensitivity to pH or temperature, and even make them
more suitable for hydrophobic or water-soluble molecules,
respectively. Delivery may be through inhalation, such as
liposomal amikacin for P. aeruginosa in cystic ﬁbrosis108 and
mycobacterial infections. Alternatively, passive targeting may be
preferred, such as blood long circulating nanocarriers that delay
hepatosplenic clearance in order to favour extravasation towards
infected tissues, such as the lungs, as well as reaching optimal
intracellular concentrations (i.e., vancomycin).109 Another ap-
proach is functionalized nanoparticles with on–off demand drug
release, which occurs only when the loaded nanoparticle comes
into contact with the speciﬁc bacterial secreted toxins,110 or even
on recognition of bacterial cell wall components; these can be
engineered to have chemical or photothermal functionality.111 The
most important advantages are a reduction in side effects,
improved drug solubility for intravenous administration, and
reduced frequency of administration.112,113 Bioconjugation with
pH-sensitive particles has also been shown to improve intracellu-
lar antibacterial activity,114 and penicillin-bound polyacrylate
nanoparticles were able to restore the activity of beta-lactam
antibiotics against MRSA.115 Among polymeric compounds, the
copolymers of poly(lactide-co-glycolide) are of particular interest
since they are biologically tolerable, may be able to cross the
intestinal barrier, and are metabolized via normal metabolic
pathways.116–119
Nebulized therapies are expected to efﬁciently increase drug
concentrations without simultaneously reaching toxic systemic
levels,120 although optimal dosing and delivery methods are still
under discussion.21 Colistin, discovered more than 50 years ago,
has been almost forgotten for decades due to its high toxicity,
inducing neuronal or kidney damage in up to half of patients, but
nebulized therapy has allowed its resurgence.121 Important issues
are the optimal method of drug delivery and the different
interpretation of minimum inhibitory concentration.
Not all types of nebulizer deliver aerosol particles with the same
efﬁciency. There are several approaches, mostly in the treatment of
cystic ﬁbrosis, where treatment with inhaled antibiotics (tobra-
mycin, colistin, or aztreonam lysine) is indicated for chronic lung
infection with P. aeruginosa, as well as the use of azithromycin and
ciproﬂoxacin dry powder.122 Clinical trials are ongoing for the
development of novel inhaled antibiotic regimens,81 including for
VAP, although there is still not enough clinical evidence.123
Adjunctive combined therapy (inhaled and intravenous) has also
been suggested to maximize therapy,124 but the recommendation
is only for those cases susceptible to aminoglycosides and
polymyxins.21
Inﬂammation of the airways and/or the lung tissue is crucial for
the secondary damage that determines signs and symptoms and
deﬁnes the switch from colonization to infection. The use of
systemic bactericidal drugs may not be superior to bacteriostatic
agents because bacterial lysis releases large amounts of cell
wall and cytosolic toxins with a consequent excessive inﬂamma-
tory reaction. For instance, inhibitors of protein synthesis such
as clindamycin, rifampicin, and linezolid also inhibit toxin
production and could become beneﬁcial125 by attenuating an
excessive inﬂammatory reaction, including decreased neutrophilinﬁltration,126 crucial in the initial innate immune response in
the lung.127
6.4. Targeting virulence factors and bioﬁlm
Although several antimicrobials alter toxin production, as
extensively reported for CA-MRSA,43,44,128,129 an alternative
approach to conventional antimicrobials, aimed at killing the
bacteria (as are almost all available antibiotics), is based on
targeting the functions essential for infection, such as virulence
factors required to cause host damage and disease, without
impairing microbial growth. Although antibody therapies in the
form of serum were the ﬁrst effective antimicrobials, the use of
puriﬁed monoclonal antibodies (mAb) has only recently reached
the ﬁeld of infectious diseases.130 This approach expands the
repertoire of bacterial targets, preserving the host endogenous
microbiome, and exerting less selective pressure, which may result
in a decreased development of antibiotic resistance,131 although
the cost is still a major obstacle.
The ﬁrst mAb licensed for LRTI was palivizumab for respiratory
syncytial virus in high-risk infants and immunocompromised
adults.132 Antibodies binding virulence factors are considered one
of the alternative approaches most likely to have a major clinical
impact and there are already several products undergoing clinical
evaluation in phase 2 trials, mostly targeting S. aureus and
P. aeruginosa.97 Regarding S. aureus, current research is focused on
mAb against alpha-haemolysin and surface proteins.133 For P.
aeruginosa, mAbs targeting lipopolysaccharide have been used as
adjunctive therapy in the treatment of nosocomial pneumonia.134
mAbs towards alginate, a cell surface polysaccharide, have been
used for hospital-acquired VAP. Finally, a multifunctional bispe-
ciﬁc antibody against type III secretion system virulence factor
PcrV and persistence factor Psl exopolysaccharide is also under
evaluation.135
The next generation of mAbs include novel targets, such as QS
molecules136 and homoserine lactones from P. aeruginosa,137 and
agr components from S. aureus,138,139 including the use of
nanoparticles.140 However, QS blockade may also increase the
prevalence of more virulent genotypes, so the ﬁnal impact has to be
assessed carefully.141 They can be used alone or as adjuncts to
current antimicrobial therapy and will be effective in hosts with
different states of immunity, so could be used as immunoprophy-
laxis or adjunctive therapy.130,139 Adjuvants can be used in
conjunction with antibiotics used to potentiate the effects of
antimicrobials and also include anti-resistance drugs such as novel
beta-lactamase inhibitors, efﬂux pump inhibitors, and outer
membrane permeabilizers.142 Several approaches include the
targeting and dispersion of bioﬁlm.29,143,144
6.5. Phage therapy
Bacteriophages were used extensively to treat bacterial
infections in the former Soviet Union. A resurgence of phage
development is now being observed as a result of many
antimicrobials being less useful due to the emergence of multidrug
resistance.
Phage therapy for pulmonary infections is interesting because
delivery can be topical and/or systemic.120 Topical application
avoids the losses associated with absorption and distribution,
increasing the potential for local achievement, including delivery
as aerosols into the lungs.145 An alternative approach is phage
endolysins, which are bacteriophage cell wall hydrolases, currently
also known as enzybiotics (protein antibiotics),146 that cleave the
major bond types in the peptidoglycan by speciﬁc cell wall
hydrolysis. Currently available evidence still supports the notion
that even lysins with a wider range of antimicrobial activity would
C. Prat, A. Lacoma / International Journal of Infectious Diseases 51 (2016) 113–122 119exert a less dramatic effect on the normal microbiota than
conventional antibiotics. It is feasible to construct new and more
lethal phage lysins from modiﬁed pre-existing enzymes that are
active against Gram-positive species, which lack the impermeable
lipopolysaccharide layer surrounding their cell wall.147,148 Recent-
ly, endolysins have been modiﬁed by protein engineering to create
outer membrane-penetrating endolysins (artilysins), rendering
them highly bactericidal against Gram-negative pathogens,
including P. aeruginosa and Acinetobacter baumannii.149 There is
also a second category of phage-encoded enzymes (EPS depoly-
merases) that digest the extracellular polymeric substance (EPS), a
particularly notable component of bacterial bioﬁlms, so they act by
reducing bacterial density of a diversity of bioﬁlms.150 Trials with
lysins and both wild-type and engineered bacteriophages are in
the pipeline.97
6.6. Antimicrobial peptides
The main advantages of antimicrobial peptides are their broad
spectrum and bactericidal activity and rapid action with lack of
immunogenicity.97 They have received attention particularly for
topical therapies151 and as anti-bioﬁlm agents152 (i.e., LL 37). It has
been shown in vitro that they can induce transient resistance, but
there is no evidence that this occurs in vivo.153 To address the
pulmonary delivery issue, exogenous surfactant has been proposed
as a carrier for a variety of biological agents.154 Clinical trials are
also ongoing targeting P. aeruginosa,155 S. aureus, and S. pneumoniae
(plectasin).156 Surfactant can assist in the delivery of an
antimicrobial peptide into the lung, as recently tested against
MRSA and P. aeruginosa as proof of concept,157 as well as with
nanoparticle delivery.158
Probiotics and nutritional supplementation might also play a
role.97,142 Another promising approach involves host-directed
immunomodulatory therapies, and this is reviewed elsewhere.159
This covers immunosuppression to immunostimulation and is
more developed in sepsis.160
7. Conclusions
The management of infections, as for many other pathologies,
requires a multidisciplinary approach. Such an approach is better
established in other clinical situations such as oncology. For the
management of respiratory tract infections including tuberculosis,
the role of the medical specialist in charge of the patient has to be
complemented by adequate communication with radiologist and
microbiologist experts. Nowadays novel diagnostic methods allow
the rapid and accurate detection and identiﬁcation of microorgan-
isms in most cases, but careful interpretation is needed. The role of
the clinical microbiologist includes giving advice regarding the
selection of adequate samples to be drawn and the diagnostic
method to be used, the interpretation of results, and a consensus
for the optimal treatment. In times of laboratory centralization,
ﬂuent communication between specialists is even more crucial,
and working teams to elaborate protocols and to discuss
conﬂicting results are needed, reaching not only hospital
specialists but also general practitioners. A permanent exchange
of knowledge between the different specialists is crucial to acquire
expertise and ﬁnally to improve management.
There is increasing evidence that treatment is only required
when the microorganism is really causing airway or tissue injury.
Understanding the host–pathogen interaction that contributes to
persistence and dissemination during colonization and infection
has to result in the proposal of a prudent treatment indication. In
our opinion, the option not to treat has to be one of the potential
decisions based on clinical, radiographic, and microbiological data,
as well as data obtained from novel diagnostic methods based onthe detection of the inﬂammatory response and virulence
pathogenesis. Regarding how to treat, novel therapeutic targets
based on virulence factors, as well as new means of administration,
dosages, and combinations of antimicrobials and adjuvants, will
contribute to reduce the adverse side effects and the emergence of
drug resistance and provide an effective delivery to the site of
infection.
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